

MenB Vaccines

Vaccine	Recommend Age	Dosage	Dosing Schedule
MenB-FHbp (Trumenba, Wyeth)	10 years and older	0.5 mL IM	Three doses* (0, 1- 2, and 6 months) Two dose schedule* (0 and 6 months)
MenB-4C (Bexsero®, Novartis)			Two doses at least 1 month apart (0 and 1-6 months)

*The choice of a dosing schedule may depend on the risk of exposure and the patient's susceptibility to meningococcal serogroups B disease.

Meningococcal Serogroup B Vaccine Recommendations

- Certain persons aged 10 years and older who are at increased risk for meningococcal disease attributable to serogroup B, including:
 - Persons with persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or taking eculizumab (Soliris®))
 - Persons with anatomic or functional asplenia, including sickle cell disease.
 - Microbiologists routinely exposed to isolates of *Neisseria meningitidis*.
 - Persons identified as at increased risk because of a serogroup B meningococcal disease outbreak.
 - Persons residing on college campuses that have recently experienced an outbreak of serogroup B meningococcal disease.
- MenB vaccine **is not** recommended for the following persons:
 - Travelers to or persons residing in countries where meningococcal disease is hyperendemic or epidemic because the risk for meningococcal disease in these countries generally is not caused by serogroup B.
 - First year college students living in residence halls or military recruits.
- MenB vaccine should be used during pregnancy **only** if clearly indicated.

Recommendations for Adolescents

- MenB vaccine may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of serogroups B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years.
- MenB vaccines are not licensed for children aged <10 years and are not currently recommended for children aged 2 months–9 years who are at increased risk for serogroup B meningococcal disease.



Contraindications

- **MenB-FHbp (Trumenba)**
Severe allergic reaction after a previous dose.
- **MenB-4C (Bexsero):**
Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose.

Precautions

- **MenB-FHbp (Trumenba) and MenB-4C (Bexsero):**
Individuals with altered immunocompetence may have reduced immune responses to MenB vaccines.

COM-PR/B71-VMB-V3 (06/14/17)

MenB-FHbp (Trumenba) Vaccination for High – Risk Persons

- For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, ACIP recommends that 3 doses of MenB-FHbp (Trumenba) be administered at 0, 1–2, and 6 months or 2 doses MenB – 4C (Bexsero) at 0 and 6 months. Recommendations regarding use of MenB-4C vaccine (Bexsero) for persons at increased risk for meningococcal disease and during outbreaks are unchanged.
- When given to healthy adolescents who are not at increased risk for meningococcal disease, ACIP recommends that 2 doses of MenB-FHbp should be administered at 0 and 6 months.

Vaccine Administration:

MenB-FHbp (Trumenba) and MenB-4C (Bexsero)

- MenB vaccine should be administered as either a 2-dose series of MenB-4C (Bexsero) or a 2 – or 3 – dose series of MenB-FHbp (Trumenba).
- The same vaccine product should be used for all doses.
- Shake syringe vigorously to ensure that a homogenous white suspension is obtained. Do not use the vaccine if it cannot be re-suspended.
- Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit; do not use if particulate matter or discoloration is found.
- Administer as a 0.5 mL dose using a sterile needle attached to the supplied prefilled syringe.
- The preferred site for injection is the deltoid muscle of the upper arm.
- Do not mix with any other vaccine in the same syringe
- May be administered simultaneously with other vaccines but in a separate injection site.

Adverse Reactions

- MenB-FHbp (Trumenba):
Local: injection site pain
Systemic: fatigue, headache, muscle pain, chills
- MenB-4C (Bexsero):
Local: injection site pain, erythema
Systematic: fatigue, headache, nausea, arthralgia, myalgia

Vaccine Storage and Handling

- Store refrigerated, at 36°F to 46°F (2°C to 8°C).
- Do not freeze. Discard if the vaccine has been frozen.
- Protect from light.

References:

Patton ME, Stephens D, Moore K, MacNeil JR. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016. *MMWR Morb Mortal Wkly Rep* 2017;66:509 – 513
www.cdc.gov/mmwr/volumes/66/wr/mm6619a6.htm